Cell Therapies

Companies Cell Therapies

Miltenyi Biotec GmbH, Germany

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Since 1989, we have developed innovative and reliable technologies for scientists and clinicians around the world. Our integrated portfolio of tools covers techniques of sample prepar more

PeproTech GmbH, Germany

PeproTech was established in 1988 by a group of scientists who focussed their efforts on the development and production of recombinant cytokines for life-science research. Today, PeproTech is a world leader in supplying high quality cytokine products including more than 350 E. coli, insect, and mamm more

Catalogues Cell Therapies

MACS® Cytokines: recombinant cytokines & growth factors

At Miltenyi Biotec, high production standards, up to GMP, ensure constant high quality. A broad choice of cytokines for demanding applications make up our portfolio more

News Cell Therapies

• ReGenesys announces Cell Therapy Manufacturing Award

  ReGenesys, subsidiary of Athersys, Inc. announced it recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its development of an automated bioreactor system for the production of MultiStem®, Athersys’ proprietary, off-the-shelf stem c more

• TiGenix's new European production facility obtains EMA approval for commercial production of ChondroCelect

  TiGenix announced that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company's commercial cell therapy product for cartilage repair in the kne more

• Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development

  Athersys, Inc.  announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform.  Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) to more

Publications Cell Therapies

• Functionalized self-assembling peptide nanofiber hydrogels mimic stem cell niche to control human adipose stem cell behavior in vitro

  Publication date: June 2013 Source:Acta Biomaterialia, Volume 9, Issue 6 Author(s): Xi Liu , Xiumei Wang , Xiujuan Wang , Hui Ren , Jin He , Lin Qiao , Fu-Zhai Cui A class of designer functionalized self-assembling peptide nanofiber scaffolds developed from self-assembling peptide RADA1 more

• TIE2‐expressing monocytes/macrophages regulate revascularization of the ischemic limb

  Abstract A third of patients with critical limb ischemia (CLI) will eventually require limb amputation. Therapeutic neovascularization using unselected mononuclear cells to salvage ischemic limbs has produced modest results. The TIE2‐expressing monocytes/macrophages (TEMs) are a myeloid cell su more

• Conditioned medium from human amniotic epithelial cells may induce the differentiation of human umbilical cord blood mesenchymal stem cells into dopaminergic neuron‐like cells

  Dopaminergic (DA) neuron therapy has been established as a new clinical tool for treating Parkinson's disease (PD). Prior to cell transplantation, there are two primary issues that must be resolved: one is the appropriate seed cell origin, and the other is the efficient inducing technique. In the more

Market studies Cell Therapies

• Thailand Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: Usage of compulsory licenses, low-capita healthcare expenditure, widespread corruption and general regulatory lapses will continue to deter investments from foreign pharmaceutical companies. This is especially so when BMI is witnessing strong growth and increased government commitment to more

• Fibrocell Sciences, Inc. (FCSC) - Financial and Strategic SWOT Analysis Review

  Fibrocell Sciences, Inc. (FCSC) - Financial and Strategic SWOT Analysis Review Summary Fibrocell Science, Inc. ( FCSI) is an autologous cellular therapeutic company. FCSI is focused on developing autologous cell therapies for aesthetic, medical and scientific applications. These therapies are de more

• Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review

  Pathfinder Cell Therapy, Inc. (Pathfinder Cell Therapy), formerly known as SyntheMed, Inc., is a biomaterial company. The company principally engages in the development and distribution of anti-adhesion surgical products. The company's product, REPEL-CV, is a bioresorbable film designed to be plac more

Websites Cell Therapies